Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison

Chan, Andrew; Cutter, Gary; Fox, Robert J.; Xiao, James; Lewin, James B.; Edwards, Michael

doi:10.2217/cer-2016-0085

Cited by 13 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DMF has also been shown to be comparable or superior to several other MS treatments. DMF-treated patients had lower annualized relapse rates and 12-week disability progression when compared with patients treated with glatiramer acetate (Chan et al, 2017). Patients who switched from firstgeneration platform disease-modifying therapies to DMF also saw reductions in annualized relapse rates and lesions, and switching to DMF treatment was found to be comparable with fingolimod and superior to teriflunomide (Fernandez et al, 2017;Prosperini et al, 2018;Ontaneda et al, 2019; Table 2).…”

Section: Nrf2 and Msmentioning

confidence: 99%

NRF2 as a Therapeutic Target in Neurodegenerative Diseases

2020

View full text Add to dashboard Cite

Increased reactive oxygen species production and oxidative stress have been implicated in the pathogenesis of numerous neurodegenerative conditions including among others Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedrich's ataxia, multiple sclerosis, and stroke. The endogenous antioxidant response pathway protects cells from oxidative stress by increasing the expression of cytoprotective enzymes and is regulated by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2). In addition to regulating the expression of antioxidant genes, NRF2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. This is because mitochondrial dysfunction and neuroinflammation are features of many neurodegenerative diseases as well NRF2 has emerged as a promising therapeutic target. Here, we review evidence for a beneficial role of NRF2 in neurodegenerative conditions and the potential of specific NRF2 activators as therapeutic agents.

show abstract

Section: Nrf2 and Msmentioning

confidence: 99%

NRF2 as a Therapeutic Target in Neurodegenerative Diseases

2020

View full text Add to dashboard Cite

show abstract

“…The CONFIRM study and subsequent post hoc analyses found DMF had greater efficacy in terms of reduction in annualised relapse rate (ARR) versus placebo or glatiramer acetate (GA) [1, 4]. Post hoc analyses of clinical trial data using mixed treatment comparisons or indirect matching-adjusted methods also found DMF was associated with improved efficacy, as mainly assessed by ARR, compared with interferons (IFN), or teriflunomide (TERI), and with similar efficacy compared with fingolimod (FTY) [2, 3, 5].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) has been shown to be effective for the treatment of relapsing–remitting multiple sclerosis (RRMS) in randomised clinical trials (RCTs), post hoc analyses, and real-world effectiveness studies [ 1 – 5 ]. The CONFIRM study and subsequent post hoc analyses found DMF had greater efficacy in terms of reduction in annualised relapse rate (ARR) versus placebo or glatiramer acetate (GA) [ 1 , 4 ]. Post hoc analyses of clinical trial data using mixed treatment comparisons or indirect matching-adjusted methods also found DMF was associated with improved efficacy, as mainly assessed by ARR, compared with interferons (IFN), or teriflunomide (TERI), and with similar efficacy compared with fingolimod (FTY) [ 2 , 3 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

et al. 2018

View full text Add to dashboard Cite

BackgroundComparative effectiveness (CE) research allows real-world treatment comparisons using outcome measurements important to physicians/patients. This German NeuroTransData registry-based analysis compared delayed-release dimethyl fumarate (DMF) effectiveness with interferons (IFN), glatiramer acetate (GA), teriflunomide (TERI), or fingolimod (FTY) in patients with relapsing–remitting multiple sclerosis (RRMS) using propensity score matching (PSM).MethodsData from registry patients aged ≥ 18 years with RRMS, ≥ 1 relapse, and Expanded Disability Status Scale (EDSS) assessment(s) after index therapy initiation underwent 1:1 PSM to match DMF with comparator populations baseline characteristics. Primary outcome measurement was time to first relapse (TTFR). Secondary outcome measurements included annualised relapse rate (ARR), proportion of patients relapse free at 12 and 24 months, time to index therapy discontinuation (TTD), and reasons for discontinuation. Exploratory analyses included time to 3- and 6-month EDSS confirmed disability progression (CDP). Non-pairwise censoring was the primary analysis method; pairwise censoring was the main sensitivity analysis method.FindingsPost-matched cohorts were well-balanced. By non-pairwise censoring, TTFR and ARR were significantly lower in DMF populations versus matched IFN, GA, and TERI, but there was no evidence of difference between DMF and FTY. TTD was similar between DMF and IFN, GA, and TERI, but significantly shorter versus FTY. Time to CDP generally showed no evidence of difference between DMF and comparator populations. Pairwise censored analysis results confirmed the non-pairwise censoring results.InterpretationThese results support previous CE studies in demonstrating relative improvement in real-world effectiveness with DMF versus first-line agents IFN, GA, and TERI, and similar effectiveness versus FTY.Electronic supplementary materialThe online version of this article (10.1007/s00415-018-9083-5) contains supplementary material, which is available to authorized users.

show abstract

“…The first, conducted by Andrew Chan et al (Bern University Hospital, Switzerland), compared two multiple sclerosis drugs in a matching-adjusted indirect comparison [11]. The second paper, from Juliana Meyers et al (RTI Health Solutions, NC, USA), was a retrospective study examining the use of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder [13].…”

mentioning

confidence: 99%

Introducing Volume 7 of the Journal of Comparative Effectiveness Research

Dormer

2018

J. Comp. Eff. Res.

View full text Add to dashboard Cite

In this issueIn this issue, we start the year with an interesting spread of commentary, original research and review content. Real-world evidence has become an important discussion point, and source of data, in recent times (as shown by some of our most read articles in 2017, see more below). This issue includes an interview from Dr Marc Berger, discussing the reports published by the joint ISPOR-ISPE Special Task Force on real-world evidence in healthcare decision making, with the goal of establishing good procedural practices for real-world data studies and ultimately increase trust in this type of research [1].In his Editorial, Skip Olson discusses the development of an integrated strategy for evidence generation, bringing together both randomized clinical trial and real-world evidence-based approaches [2].In a new White Paper, Hampson et al. discuss the outcomes of an Institute for Clinical and Economic Review policy forum, exploring the challenges presented by gene therapies, discussing potential solutions and presenting policy recommendations [3].Also in this issue is a range of research and review content, including a Methodology paper discussing the Platform for Haematology in EMEA: Data for Real World Analysis (PHEDRA) [4]; and research on hemophilia B [5] and hemorrhage following cesarean delivery [6].This issue is completed with a protocol paper describing the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study [7] and a Systematic Review article examining treatments, quality of life and costs in metastatic breast cancer [8].

show abstract

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison

Cited by 13 publications

References 40 publications

NRF2 as a Therapeutic Target in Neurodegenerative Diseases

NRF2 as a Therapeutic Target in Neurodegenerative Diseases

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Introducing Volume 7 of the Journal of Comparative Effectiveness Research

Contact Info

Product

Resources

About